Genetics
Meta-analysis links the CETP C-629A polymorphism to higher coronary heart disease risk and circulating CETP in Caucasians (Oncotarget 2017)
Original title: A meta-analytic evaluation of cholesteryl ester transfer protein (CETP) C-629A polymorphism in association with coronary heart disease risk and lipid changes
A meta-analysis of 17 studies (5441 patients and 7967 controls) evaluated whether the CETP C-629A polymorphism is associated with coronary heart disease (CHD) risk and lipid changes. Overall the polymorphism was not significantly associated with CHD risk, but subgroup analysis in Caucasians found the -629C allele increased CHD odds 1.18-, 1.43-, and 1.41-fold under allelic, genotypic, and dominant models respectively (P < 0.001), and increased myocardial infarction risk by 1.23-, 1.28-, and 1.29-fold (P < 0.02). Carriers of the -629C allele also had higher circulating CETP (weighted mean difference 0.45 ug/mL; 95% CI, 0.25 to 0.65; P < 0.001) and lower HDL cholesterol (weighted mean difference -3.65 mg/dL; 95% CI, -5.59 to -1.70; P < 0.001) than -629AA homozygotes, suggesting the CHD association is mediated through the effect of CETP on HDL-C.
Original abstract
Lipid metabolism plays an essential role in the pathogenesis of atherosclerosis, a major cause for coronary heart disease (CHD). Cholesteryl ester transfer protein (CETP) is an important glycoprotein involved in lipid metabolism by transferring cholesteryl esters to apolipoprotein B-containing lipoproteins in exchange for triglycerides. The objective of this meta-analysis was to evaluate the association of CETP C-629A polymorphism with CHD risk and lipid changes. Four public databases were searched, and data from 17 qualified articles were extracted in duplicate and analyzed by STATA software. Overall association of C-629A with CHD risk was nonsignificant in 5441 patients and 7967 controls. Subgroup analyses by ethnicity revealed significance only in Caucasians, with the odds of CHD being 1.18, 1.43 and 1.41 under allelic, genotypic and dominant models, respectively (P < 0.001). Similarly, the -629C allele increased the corresponding risk of myocardial infarction by 1.23-, 1.28- and 1.29-fold (P < 0.02). The association of C-629A with CHD was significantly strengthened in prospective and large studies. Moreover, carriers of the -629C allele had significant higher levels of circulating CETP (weighted mean difference [WMD]: 0.45 μg/mL; 95% confidence interval [CI]: 0.25 to 0.65; P < 0.001), but lower levels of high-density lipoprotein cholesterol (HDL-C) (WMD: -3.65 mg/dL; 95% CI: -5.59 to -1.70; P < 0.001) relative to the -629AA homozygotes. The probability of publication bias was low. Our meta-analytic findings collectively demonstrate that the -629C allele was significantly associated with an increased risk of CHD in Caucasians, and this association may be mediated by its phenotypic regulation on circulating CETP and HDL-C.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.